Ensysce Biosciences secures $1.7M convertible note financing

Ensysce Biosciences entered into a securities purchase agreement with investors in the form of senior secured convertible notes and warrants exercisable for Ensysce common stock in a private placement for an aggregate investment of $1.7 million. The initial closing is expected to occur on or before October 26th and will raise $566,667, prior to fees and offering expenses.